Published in Haemophilia on September 01, 2007
Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus (2014) 1.46
Barriers and perceived limitations to early treatment of hemophilia. J Blood Med (2013) 1.04
Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cells. Mol Ther (2011) 0.85
Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol (2013) 0.83
Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts. Mol Ther (2009) 0.82
A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Blood Transfus (2011) 0.80
Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. Drug Des Devel Ther (2010) 0.79
Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood (2016) 0.79
Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders. Blood Transfus (2014) 0.78
Economic burden of high-responding inhibitors in patients with hemophilia A in Taiwan. Yonsei Med J (2013) 0.77
Physical and psychosocial challenges in adult hemophilia patients with inhibitors. J Blood Med (2014) 0.76
Key issues in inhibitor management in patients with haemophilia. Blood Transfus (2013) 0.76
Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors. Blood Transfus (2015) 0.75
Strategies to encourage physical activity in patients with hemophilia to improve quality of life. J Blood Med (2016) 0.75
Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes. Ther Adv Drug Saf (2011) 0.75
Pain and pain management in haemophilia. Blood Coagul Fibrinolysis (2016) 0.75
Compartment syndrome in patients with haemophilia. J Orthop (2015) 0.75
Tailoring care to haemophilia patients' needs: which specialty and when? Blood Transfus (2015) 0.75
Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX. J Clin Med (2017) 0.75
Immune tolerance induction in patients with severe hemophilia A with inhibitors. Blood Res (2015) 0.75
Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors. J Blood Med (2011) 0.75
The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors. Blood Res (2015) 0.75
Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet (1993) 5.11
Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest (2001) 2.84
Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders. Haemophilia (2010) 2.03
Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Thromb Haemost (1991) 1.94
The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia (2004) 1.92
Thalidomide treatment in advanced refractory myeloma. Br J Haematol (2000) 1.71
Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg (1994) 1.69
Treatment for haemophilia by postcode. BMJ (1997) 1.67
The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis (1996) 1.62
Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia (2010) 1.59
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Mitochondrial function in the oxygen depleted and reoxygenated myocardial cell. Cardiovasc Res (1994) 1.57
Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia (2009) 1.55
Hemophilic pseudotumor: multicenter experience over a 25-year period. Am J Hematol (1994) 1.53
Pancreatic carcinoma in azaserine-treated rats: induction, classification and dietary modulation of incidence. Cancer (1981) 1.47
Mild bleeding diathesis in a boy with combined severe haemophilia B (C(10400)-->T) and heterozygous factor V Leiden. Haemophilia (2001) 1.43
[The 2013 Seville Consensus Document on alternatives to allogenic blood transfusion. An update on the Seville Document]. Rev Esp Anestesiol Reanim (2013) 1.37
Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol (2007) 1.32
Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J Immunol (2000) 1.31
Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol (1998) 1.30
[Clinical practice guideline on diagnosis and treatment of Crohn's disease]. Z Gastroenterol (2008) 1.19
Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther (2000) 1.19
Interaction of hepatitis B and hepatitis C infection in haemophilia. Br J Haematol (1993) 1.17
What you eat is what you get: Novel Campylobacter models in the quadrangle relationship between nutrition, obesity, microbiota and susceptibility to infection. Eur J Microbiol Immunol (Bp) (2011) 1.15
Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol (2004) 1.14
High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology (2004) 1.13
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut (2008) 1.13
Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg (2000) 1.13
Toll-like receptor expression and response to specific stimulation in adipocytes and preadipocytes: on the role of fat in inflammation. Ann N Y Acad Sci (2006) 1.09
Human parvovirus B19 antibodies are less frequent among patients treated with factor IX concentrate inactivated by ultrafiltration: a report from a single Spanish institution. Vox Sang (1998) 1.06
Longevity of adult ventricular rat heart muscle cells in serum-free primary culture. J Mol Cell Cardiol (1991) 1.06
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost (2005) 1.06
Intrascleral schwannoma. Ophthalmologica (1976) 1.05
Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia (2009) 1.05
Spontaneous superficial venous thrombophlebitis: does it increase risk for thromboembolism? A historic follow-up study in primary care. J Fam Pract (2006) 1.04
Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia (2007) 1.02
Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia (2006) 1.01
Comparison of capillary whole blood, venous whole blood, and plasma concentrations of mefloquine, halofantrine, and desbutyl-halofantrine measured by high-performance liquid chromatography. Am J Trop Med Hyg (1994) 1.01
Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol (2002) 1.00
Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. Allergy (2011) 1.00
Defining the role of T cell-derived leptin in the modulation of hepatic or intestinal inflammation in mice. Clin Exp Immunol (2005) 0.99
Malignant solitary fibrous tumour of the orbit: report of a case with 8 years follow-up. Eye (Lond) (2001) 0.99
Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia (2008) 0.99
Antibody response to pre-S2 and hepatitis B virus induced liver damage. Lancet (1988) 0.99
Metabolism of exogenous substrates by coronary endothelial cells in culture. J Mol Cell Cardiol (1990) 0.97
Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis. Thromb Haemost (1998) 0.97
Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med (1999) 0.96
Left ventricular isovolumic velocity and duration variables calculated from colour-coded myocardial velocity images in normal individuals. Eur J Echocardiogr (2004) 0.96
Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia (2004) 0.95
Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol (2002) 0.93
Adipokine signaling in inflammatory bowel disease. Inflamm Bowel Dis (2009) 0.93
Prevention of the oxygen paradox in hypoxic-reoxygenated hearts. Am J Physiol (1991) 0.93
The distinct roles of MMP-2 and MMP-9 in acute DSS colitis. Eur J Microbiol Immunol (Bp) (2011) 0.93
Coeliac axis thrombosis associated with the combined oral contraceptive pill: a rare cause of an acute abdomen. Pediatr Surg Int (1998) 0.92
Emergency perception and other variables associated with extra-hospital delay in stroke patients in the Maresme region (Spain). Eur J Neurol (2008) 0.91
Effect of age upon the induction and maintenance of anticoagulation with warfarin. Postgrad Med J (1995) 0.91
Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis (2002) 0.91
The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia (2011) 0.90
Development of a new disease-specific quality-of-life questionnaire to adults living with haemophilia. Haemophilia (2004) 0.90
Intra-articular rifamycin in haemophilic arthropathy. Haemophilia (2003) 0.89
A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia (2011) 0.89
Importance of bicarbonate transport for protection of cardiomyocytes against reoxygenation injury. Am J Physiol Heart Circ Physiol (2000) 0.89
Haemophilia care then, now and in the future. Haemophilia (2009) 0.89
Independence of restrictive filling pattern and LV ejection fraction with mortality in heart failure: an individual patient meta-analysis. Eur J Heart Fail (2008) 0.89
Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Haemophilia (2000) 0.88
Osteopontin predicts long-term functional outcome among ischemic stroke patients. J Neurol (2010) 0.88
Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost (2001) 0.88
The role of Na+/H+ exchange in ischemia-reperfusion. Basic Res Cardiol (1996) 0.88
Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia (2005) 0.88
Antibody to hepatitis C virus and liver disease in volunteer blood donors. Ann Intern Med (1991) 0.88
Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol (2001) 0.87
Relapsing polychondritis and myelodysplasia: a report of two cases and review of the current literature. Clin Lab Haematol (2000) 0.87
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A. Haemophilia (2006) 0.87
Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk? Haematologica (2004) 0.87
Vitamin K-dependent coagulation parameters during the first six days of life: incidence of PIVKA II in newborns. Pediatr Hematol Oncol (1989) 0.86
Lipoprotein (a): its role in childhood thromboembolism. Pediatrics (1997) 0.86
Severe haemophilia A in a female resulting from an inherited gross deletion and a de novo codon deletion in the F8 gene. Haemophilia (2008) 0.86
Selective gelatinase blockage ameliorates acute DSS colitis. Eur J Microbiol Immunol (Bp) (2011) 0.86
Resistance of endothelial cells to anoxia-reoxygenation in isolated guinea pig hearts. Am J Physiol (1989) 0.86
Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost (2009) 0.86
A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia (2001) 0.86
A framework for genetic service provision for haemophilia and other inherited bleeding disorders. Haemophilia (2005) 0.86
Participation in sports and physical activity of haemophilia patients. Haemophilia (2007) 0.85
Mesenteric fat - control site for bacterial translocation in colitis? Mucosal Immunol (2012) 0.85
Reflecting on the use of student portfolios. Nurse Educ Today (2001) 0.85
Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. Br J Haematol (1993) 0.84
Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol (1996) 0.84
ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia (2007) 0.84
Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene. Br J Haematol (2001) 0.84
Biomarker level improves the diagnosis of embolic source in ischemic stroke of unknown origin. J Neurol (2012) 0.84
Protection of reoxygenated cardiomyocytes against hypercontracture by inhibition of Na+/H+ exchange. Am J Physiol (1995) 0.84
Calcium and sodium control in hypoxic-reoxygenated cardiomyocytes. Basic Res Cardiol (1994) 0.84
C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol Scand (2007) 0.83
One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia (2008) 0.83
Presumed melanocytoma of the macula. Arch Ophthalmol (1994) 0.83
Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia (2009) 0.83